Oruka Therapeutics’ (ORKA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research note issued to investors on Thursday, Marketbeat Ratings reports. The firm currently has a $120.00 target price on the stock.

Several other equities research analysts have also issued reports on ORKA. BTIG Research reissued a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. UBS Group upped their price target on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Finally, Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $128.91.

Oruka Therapeutics Price Performance

ORKA opened at $84.46 on Thursday. Oruka Therapeutics has a 12 month low of $15.00 and a 12 month high of $115.51. The business has a 50-day moving average of $96.67 and a two-hundred day moving average of $75.75. The stock has a market capitalization of $5.59 billion, a price-to-earnings ratio of -41.61 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Equities research analysts anticipate that Oruka Therapeutics will post -2.42 earnings per share for the current year.

Insider Buying and Selling

In other news, SVP Arjun Agarwal sold 533 shares of the firm’s stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $95.75, for a total transaction of $51,034.75. Following the completion of the sale, the senior vice president directly owned 14,219 shares in the company, valued at $1,361,469.25. This trade represents a 3.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $92.38, for a total value of $734,143.86. Following the sale, the insider directly owned 31,771 shares in the company, valued at approximately $2,935,004.98. The trade was a 20.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 122,950 shares of company stock valued at $11,528,806 in the last quarter. Company insiders own 23.49% of the company’s stock.

Hedge Funds Weigh In On Oruka Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Sei Investments Co. grew its holdings in Oruka Therapeutics by 136.0% during the 1st quarter. Sei Investments Co. now owns 22,840 shares of the company’s stock worth $1,120,000 after acquiring an additional 13,164 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Oruka Therapeutics in the 1st quarter valued at about $5,543,000. Handelsbanken Fonder AB acquired a new stake in shares of Oruka Therapeutics in the 2nd quarter valued at about $15,313,000. The Manufacturers Life Insurance Company raised its stake in shares of Oruka Therapeutics by 18.3% in the 1st quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company’s stock valued at $3,559,000 after purchasing an additional 11,205 shares in the last quarter. Finally, Braidwell LP bought a new position in shares of Oruka Therapeutics during the second quarter worth about $26,473,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

Oruka Therapeutics News Roundup

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Positive psoriasis data: ORKA-001 produced deeper psoriasis clearance at Week 28 in the EVERLAST-A Phase 2a study, supporting the durability of the treatment’s efficacy. Analysts said the therapy maintains a competitive profile. ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data
• Positive Sentiment: Analyst support remains strong: Wedbush reaffirmed an “Outperform” rating with a $165 price target, while HC Wainwright reiterated its “Buy” rating and $120 target. Additional analyst commentary characterized ORKA as a bullish healthcare opportunity. Wedbush Rating
• Positive Sentiment: Pipeline advancing: Oruka provided an update on its ongoing ORKA-002 hidradenitis suppurativa study, a randomized, double-blind, placebo-controlled clinical trial. Progress in a second indication could broaden the company’s future commercial opportunity. ORKA-002 Trial Progress
• Neutral Sentiment: Short-interest data is inconclusive: A report listed short interest at zero shares and a zero-day short-interest ratio as of September 24, suggesting the data may be incomplete or anomalous rather than signaling a meaningful change in bearish positioning.
• Negative Sentiment: Safety disclosures offset efficacy gains: ORKA shares weakened even after the positive Week 28 results, with safety information apparently prompting investor caution. The reaction indicates that market participants may need more clarity on the treatment’s benefit-risk profile before assigning greater value to the program. Oruka’s Psoriasis Treatment Maintains Competitive Profile

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.